title: The number of CD34(+) cells in peripheral blood as a predictor of the CD34(+) yield in patients going to autologous stem cell transplantation.
abstract: The number of CD34(+) cells in peripheral blood (PB) is a guide to the optimal timing to harvest peripheral blood progenitor cells (PBPC). The objective was to determine the number of CD34(+) cells in PB that allows achieving a final apheresis product containing > or =1.5 x 10(6) CD34(+) cells/kg, performing up to three aphereses. Between March 1999 and August 2003, patients with hematological and solid malignancies who underwent leukapheresis for autologous bone marrow transplantation were prospectively evaluated. Seventy-two aphereses in 48 patients were performed (mean 1.45 per patient; range 1-3). PBPC were mobilized with cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (G-CSF) (n = 40), other chemotherapy drugs plus G-CSF (n = 7), or G-CSF alone (n = 1). We found a strong correlation between the CD34(+) cells count in peripheral blood and the CD34(+) cells yielded (r = 0.903; P < 0.0001). Using receiver-operating characteristic (ROC) curves, the minimum number of CD34(+) cells in PB to obtain > or =1.5 x 10(6)/kg in the first apheresis was 16.48 cells/microL (sensitivity 100%; specificity 95%). The best cut-off point necessary to obtain the same target in the final harvest was 15.48 cells/microL, performing up to three aphereses (sensitivity 89%; specificity 100%). In our experience, > or =15 CD34(+) cells/microL is the best predictor to begin the apheresis procedure. Based on this threshold level, it is possible to achieve at least 1.5 x 10(6)/kg CD34(+) cells in the graft with < or =3 collections.
authors.affiliation: Division of Hematology and Oncology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina. anabasquiera@arnet.com.ar
authors.forename: A L
authors.initials: AL
authors.lastname: Basquiera
authors.forename: P
authors.initials: P
authors.lastname: Abichain
authors.forename: J C
authors.initials: JC
authors.lastname: Damonte
authors.forename: B
authors.initials: B
authors.lastname: Ricchi
authors.forename: A G
authors.initials: AG
authors.lastname: Sturich
authors.forename: E D
authors.initials: ED
authors.lastname: Palazzo
authors.forename: J J
authors.initials: JJ
authors.lastname: García
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34; D001773:Blood Cells / Q000166:cytology; D016026:Bone Marrow Transplantation / Q000379:methods; D002648:Child; D002675:Child, Preschool; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007937:Leukapheresis / Q000592:standards*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation / Q000592:standards*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012372:ROC Curve; D014182:Transplantation, Autologous
chemical_list: D018952:Antigens, CD34